Publications by authors named "D H Elliott"

Bone marrow transplantation (BMT) is mainly performed to restore an anti-tumor immune response, called the graft-versus-tumor (GVT) effect, against leukemia, myeloma and lymphoma. This GVT reactivity is driven by donor T cells, and it can also cause lethal graft-versus-host disease (GVHD). We previously demonstrated that the colonization of mice with helminths preserves the GVT response while suppressing GVHD.

View Article and Find Full Text PDF

Prostate-specific membrane antigen (PSMA) PET was approved by the U.S. Food and Drug Administration in 2020 for the staging of newly diagnosed prostate cancer, yet rates of adoption and real-world positivity rates are unknown.

View Article and Find Full Text PDF

The cellular concentrations of splicing factors (SFs) are critical for controlling alternative splicing. Most serine and arginine-enriched (SR) protein SFs regulate their own concentration via a homeostatic feedback mechanism that involves regulation of inclusion of non-coding 'poison exons' (PEs) that target transcripts for nonsense-mediated decay. The importance of SR protein PE splicing during animal development is largely unknown despite PE ultra-conservation across animal genomes.

View Article and Find Full Text PDF

Background: Although the challenges of recruiting to randomised controlled trials (RCTs) are well documented, few studies have focused on the impact that the communication between recruiters and patients has on patients' participation decisions. Recruiters are thought to influence patient decision-making, but the mechanisms by which this occurs are unclear. The aim of this research was to investigate how patients interpret and use the information conveyed to them by healthcare professionals (HCPs) in trial participation decisions.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates how SARS-CoV-2 monoclonal antibody (mAB) therapy affects the immune response in five cancer patients infected with the virus, comparing them to non-mAB-treated controls.
  • - Blood samples were analyzed for various immune responses, revealing that all patients produced antibodies and T-cell responses similar to those of controls, despite some having B-cell deficiencies.
  • - The findings indicate that mAB therapy results in a robust immune response against SARS-CoV-2 in cancer patients, showing the potential for effective protective immunity even with underlying malignancies.
View Article and Find Full Text PDF